From: Galectin-3: its role in asthma and potential as an anti-inflammatory target
Disease | Method and assay | Level in blood (ng/ml) | Comments |
---|---|---|---|
Heart failure | ELISA (BG Medicine, Waltham, USA). | Decrease in left ventricular systolic function (LVEDV): 14.7(12.8-18.2); stable LVEDV: 17.9(13.7-22); increase in LVEDV: 19(14.9-24.4). | Patients were divided into three groups according to the change in LVEDV: decrease in LVEDV > 8%, stable LVEDV (−8–8%) and an increase in LVEDV > 8%. Plasma Gal-3 is associated with left ventricular remodeling determined by serial echocardiography and predicts long-term mortality in patients with severe chronic heart failure [27]. |
Rheumatoid arthritis (RA) | ELISA (R&D Systems, Minneapolis, USA). | Gal-3 was elevated in RA serum and synovial fluids. In RA, serum Gal-3 correlated with C-reactive protein levels. | Gal-3 is not only involved in inflammation, but also contributes to the activation of synovial fibroblasts [28]. |
Juvenile idiopathic arthritis (JIA) | ELISA (R&D Systems, Minneapolis, USA). | Healthy controls: 8.1(4.9–16.7); inactive disease: 18.6(9.7–28.8); active disease: 35.8(15.8–60.8). | Serum levels of Gal-3 are highest in active JIA children, followed by inactive disease and controls [29]. |
Behçet’s disease (BD) | ELISA (R&D Systems, Minneapolis, USA). | Active BD patients: 13.08 ± 1.53; inactive BD patients: 8.08 ± 0.71; healthy controls: 7.59 ± 0.48. | Active BD patients had significantly higher levels of serum Gal-3 than inactive patients and controls [30]. |
Cancer | In house ELISA | Healthy control: 62(20–313); Breast cancer: 100(20–620); Gastrointestinal cancer: 185(20–950); Lung cancer: 171(20–807). | Serum Gal-3 levels were significantly higher in subpopulations of patients having each type of tumor [31]. |
 | ELISA (Bender MedSystems, Vienna, Austria). | Controls: 3.07 ± 0.69; Colorectal cancer: 6.81 ± 4.07 | Gal-3 ranged higher in cancer patients than in controls [32]. |
 | ELISA (Human Gal-3 Assay Kit, IBL) | Bladder cancer: 1.07(0.55-2.03) Control: 0.58(0.26-1.26) | Serum Gal-3 concentration of the bladder cancer patients was higher than that of controls [33]. |
Asthma | ELISA (R&D Systems, Minneapolis, USA). | Asthma serum: 1.5(1.1-1.9); healthy control: 1.8(0.8-2.1). | Gal-3 in asthma serum was lower than that of controls (not published). |